Diabetes and Weight Loss Drug Semaglutide May Also Treat Liver Disease

This Research was A Phase 3 Clinical Trial Involve People With Metabolic Dysfunction-Associated Steatohepatitis (MASH). As described in This Study, Mash is a Severe Type of What used to be strased nalcoholic fatty liver disease.

The Study Also Notes That Mash Involves Damage to Liver Cells, Inflammation, and Steatosis or Fat Buildup in the Liver. Steatohepatitis, Which Involves Fat Buildup and inflammation in the Liver, Can Then contributes to tissue scarring or fibrosis.

This Study Involved participants from Hundreds of Clinical Sites in Thirty-Seven Countries. The Current Published results report the end of the first part of the trial.

Among the participants, 534 Received Semaglutide, and 266 Planbo. The Research Reported in This Study Lasted 72 Weeks. Participants Received 2.4mg Injection of Semaglutide Each Week, and They Followed at 16-Week dose Escalation Schedule.

All participants were at least 18 years old and had steatohepatitis and fibrosis. Excluded participants who had other chronic liver problems Besides nalcoholic fatty liver disease. OTHER EXCLUDED CRITERIA INCLUDED COMPONTS Like alcohol Consumption Over A Certain Amount and Use of LPG-1 receiver Agonists in the Three Months Leading Up To Screening. All participants Also Received Standard Care for Mash. Participants Got Two Liver Biopsies to Help Evaluate The Effects of Semaglutide.

About 56% of participants Had Type 2 Diabetes, and About 73% Had Obesity.

The Refers Evaluated Participants for Two Main Outcomes: Resolution of Steatohepatitis, Where Liver Fibrosis Didn’t Get Worse, and Improved Fibrosis, WHERE Steatohepatitis Did Not Get Any Worse. Refrachers Also Evaluated Participants For Weight Changes, Pain, Adverse Events, and Labs.

Semaglutide appeared to benefit participants more than the placebo. ALMOST 63% OF PARTICIPATIONS WHHO Received Semaglutide Had Steatohepatitis Resolution without Their Fibrosis Getting Worse. Only 34.3% of participants in the placebo Group Experienced This Outcome.

Additionionally, 36.8% of participants Who Received Semaglutide Experienced Dentales in Liver Fibrosis Without their Steatohepatitis Getting Worse, Compared to 22.4% in the placebo Group. Similar results were in sensitivity analyzes that consider components like age, diabetes, and how bad fibrosis was.

Additionionally, Sub participants Experienced Steatohepatitis Resolution and Decuesta Fibrosis. About 33% of the Semaglutide Group Experienced This Compared to About 16% in the Placebo Group.

Semaglutide’s Effects on Weight Loss, Inflammation, and Pain

The Semaglutide Group Also Experienced An Avenge 10.5% Decrease in Body Weight Comparked to Only An Average 2% Decree in the Placebo Group. WHILE IT DID NOT REACH STATISTICAL SIGNIRE, PARTICIPATIONS TAKING SEMAGLUTIDE ALSO APPEARED TO EXPERIENCE PAIN DECREASES MORE THAN THE PLACEBO GROUP.

Participants in the Semaglutide Group Had Better Outcomes from Non-Invasive Testing as Well. For Example, More Participants Taking Semaglutide Experienced Decosed Enhanced Liver Fibrosis Scores and Deciested Liver Stiffness The participants on the placebo.

Other outcomes were Better in the Semaglutide Group, Too, Such as Greater Decuees in Systemic Inflammmation and Cholesterol, as Well As Better Insulin Sensitivity.

Around 86% of participants in the Semaglutide Group reported an adverse event, compared to about 80% in the placebo Group. The Semaglutide Group Also Experienced More Gastrointestinal Events, Like Nausa and Constipation, Than The Placebo Group. However, Found That’s Refrachers “No New Or Liver-Related Safety Signals Emerged.”

Overall, The Results of This Study Indicate That Sumaglutide May Help Improve Liver Outcomes for People With Mash. However, It Does Have Limitations.

First, The Research Only Included to Small Number of Black Participants, as Well As a Low Number of Lean Participants. There May Be a Need for More Diversity in Future Research, and It’s Unclear How the Use of Semaglutide Benefits Lean Individuals with Mash. DID not have data on biomarkers for alcohol consumption. They Also Acknowledge that Genetic Variations Are Part of What Determines How Subone Responds To Treatment.

This Trial Is Ongoing and Will Have Additional Follow-Up That Will Focus on Cirrhosis-Free Survival. THUS, DID NOT SHARE INFORMATION CLINICAL OUTCOMES IN THIS PAPER FOR REASONS OF STUDY INTEGITY. This part of the study included 800 randomized participants, and This did not have to do with How well participants were following taking taking semaglutide or the placebo or certainty medication changes. Additionionally, There was Missing Data.

Researchers ACKNOWLEDGE THAT SEMAGLUTIDE HELPED TO ADDRESS PROBLEMS OF METABOLIC DYSFUNCTION THAT DRIVE LIVER PROBLEMS AND HOLISTICALLALLL HELPED ADDRESS “LIVER DISPLAY AND ASSOCIATED CARDIOMETABOLIC ILLNESS.

It’s a possibilities that the findings of This Research are the results of Weight Loss. Mir Ali, MD, Board Certified General Surgeon, Bariatric Armengon, and Medical Director of Memorialcare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, Ca, Who Was Not Involved in The Study, Note The Following To Medical News Today:

“This Study Showed A Reduction of Mash with Semaglutide Use; However, Because The Greatest Contributor To Mash is Obesity, I Believe This Is More A Function of Weight Loss than A Direct Effect of the Medication. We see significant improvment in mash in Our Surgical Patients, and it sems to be directly related to the amount of weight lost.

This Research Holds Promise for Helping People with Mash and Suggests Another Potential Benefit of Semaglutide.

Ian Storch, Do, An Osteopathic Physician Specializing in Gastroenterology and Internal Medicine and An American Osteopathic Association Member, Who Was Also Not Involved in the Study, explained to MNT:

“Mash (Metabolic Associated Hepatitis) Is Such an Important Disease, Which Didn’t Get Much Attention in the Past for Two Reasons, One Being Our Deficiety in Cost-Effective Noninvasive Imaging Modalities to Assess Fibrosis and The Second Being Our Lack of Treatment of Treatment Modalities. NEJM SHOWING Possible Benefits of Semaglutide in Mash Patieves With Advanced Inflammation and Fibrosis is Another Excithing Advance in Our Efforts To Conquer This Indolent, But Deadly Disease. ”